Core Viewpoint - Tong Ren Tang Yi Yang is making a third attempt to submit its prospectus for a Hong Kong IPO, with CICC as the sole sponsor, aiming to become the fourth listed company under the Tong Ren Tang Group [1] Group 1: Company Overview - Tong Ren Tang Yi Yang has become the largest non-public Chinese medicine hospital group in terms of outpatient and inpatient visits, holding a market share of 1.7% [2] - The company reported revenues of 911 million yuan, 1.153 billion yuan, and 1.175 billion yuan for the years 2022, 2023, and 2024 respectively, with adjusted net profits of -9.23 million yuan, 47.87 million yuan, and 61.73 million yuan [2] - The acquisition of Sanxi Tang has significantly contributed to the company's performance, generating revenues of 199 million yuan, 360 million yuan, and 374 million yuan from 2022 to 2024, accounting for 21.9%, 31.2%, and 31.8% of total revenue [2] Group 2: Acquisition and Shareholding Structure - In June 2022, three companies under the Tong Ren Tang Group became shareholders of Sanxi Tang, including Tong Ren Tang Yi Yang [3] - By March 2024, the shareholding of Tong Ren Tang Yi Yang in Sanxi Tang increased to 75% after other shareholders exited [3] - The original controlling shareholders of Sanxi Tang became shareholders of Tong Ren Tang Yi Yang through capital increase, holding a combined 3.87% stake [3] Group 3: Product Sales and Financial Performance - In January 2024, Sanxi Tang obtained exclusive sales rights for the An Gong Niu Huang Wan series in Zhejiang Province, contributing 73.149 million yuan in sales revenue for the year [6] - The sales price for An Gong Niu Huang Wan (natural version) is 860 yuan per box, with 60,000 boxes sold in 2024 [6] - The gross profit margin for Tong Ren Tang Yi Yang has been declining, with rates of 39.6%, 20.2%, and 17.9% from 2022 to 2024, attributed to reduced sales of high-margin products [7] Group 4: Related Party Transactions - In 2024, Tong Ren Tang and its controlled company contributed 20.252 million yuan in revenue to Tong Ren Tang Yi Yang [8] - The company plans to significantly increase its procurement from the Tong Ren Tang Group, with projected purchases of approximately 70 million yuan and 95 million yuan in 2025 and 2026 respectively [7]
同仁堂的资本局:扶持医养公司,三“闯”港交所